---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-183258"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2022-06-28T23:59:59+00:00"
generated_at: "2026-06-24T22:40:43.741268+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant reports Q4 net loss $0.39, VTAMA approved, $2.1B cash, pipeline reprioritized

## Summary
- Net loss $291M in Q4 ($0.39/share); full-year net loss $924M ($1.26/share); revenue $9.2M Q4 vs $15.1M prior year.
- VTAMA (tapinarof) approved by FDA for plaque psoriasis in May; launch underway with 100+ person commercial team.
- Cash and equivalents $2.1B; company discontinued several programs including ARU-1801, DMVT-502/503/504.
- Melissa Epperly appointed to Board of Directors effective June 29, replacing Pat Machado.
- Pipeline milestones: Priovant initiated Phase 3 for brepocitinib in dermatomyositis; Immunovant Phase 3 in MG started.

## SEC filing metadata
- accession: 0001193125-22-183258
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2022-06-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/d372791d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-183258
- JSON: https://secwatch.observer/filing/0001193125-22-183258.json
- Plain text: https://secwatch.observer/filing/0001193125-22-183258.txt

## Key facts
- Executive change
  Patrick Machado resigned as Director at Roivant Sciences Ltd..
  - Action: resigned
  - Role: Director
  source text: the previously announced resignation of Patrick Machado from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm
- Executive change
  Melissa Epperly was appointed as Director at Roivant Sciences Ltd..
  - Action: appointed
  - Role: Director
  source text: On June 22, 2022, the Board of Directors (the “Board”) of the Company appointed Melissa Epperly to serve as a Class I director of the Board and as a member of the Audit Committee of the Board, effective June 29, 2022, filling the vacancy created by, and concurrent with, the previously announced resignation of Patrick Machado from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.